Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript [Seeking Alpha]
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: Seeking Alpha
Company Participants Sharon Klahre - Vice President of Investor Relations & Communications Michael Metzger - CEO & Director Nicholas Botwood - Head of Research & Development and Chief Medical Officer Steven Closter - Chief Commercial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Kevin Strang - Goldman Sachs Group, Inc., Research Division Bradley Canino - Guggenheim Securities, LLC, Research Division Yuxi Dong - Jefferies LLC, Research Division Peter Lawson - Barclays Bank PLC, Research Division Ellen Horste - TD Cowen, Research Division Justin Zelin - BTIG, LLC, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, everyone, and welcome to the Syndax Conference Call to Discuss the FDA approval of Revuforj in Relapsed/R
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Syndax Announces Participation at the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth [Seeking Alpha]Seeking Alpha
- Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating [Yahoo! Finance]Yahoo! Finance
SNDX
Earnings
- 11/3/25 - Beat
SNDX
Sec Filings
- 12/1/25 - Form 4
- 11/3/25 - Form 10-Q
- 11/3/25 - Form 8-K
- SNDX's page on the SEC website